| Business Summary | | AVAX
Technologies,
Inc.
is
a
development
stage
biotechnology
company
with
international
operations,
specializing
in
the
development
and
commercialization
of
individualized
therapies
and
other
novel
products
and
technologies
for
the
treatment
of
cancer
and
other
life-threatening
diseases.
AVAX's
lead
development
program
is
a
patented
autologous
cell
technology,
called
AV
Vaccine,
that
attempts
to
stimulate
a
patients
own
immune
system
to
recognize,
contain
and
eliminate
cancer
cells.
In
August
2000,
AVAX
acquired
Genopoietic
S.A.
and
its
corporate
affiliate,
which
develops
cell
and
gene-based
therapies
in
collaboration
with
Pierre
et
Marie
Curie
University
and
Centre
National
de
la
Recherche
Scientifique.
Through
this
acquisition,
AVAX
is
developing
a
gene
therapy
technology
based
on
the
thymidine
kinase
gene
to
induce
bone
marrow
and
solid
organ
transplantation
tolerance,
for
the
treatment
of
cancer
and
other
indications,
and
autologous
chondrocytes
for
the
repair
of
damaged
cartilage. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AVAX
Technologies,
a
development
stage
company,
develops
and
commercializes
novel
biotechnologies,
immunotherapies
and
pharmaceuticals
for
cancer
and
other
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
revenues
totalled
$294
thousand,
up
from
$0.
Net
loss
increased
24%
to
$5.8
million.
Results
reflect
the
launch
of
M-Vax
in
Australia
and
the
Genopoietic
and
GPH,
S.A.
acquisition,
offset
by
the
inclusion
of
acq.
R&D
and
higher
manufacturiang
and
R&D
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| David Tousley, 45 Interim
Pres & CEO, Chief Financial Officer, Chief Operating Officer, Secy. | $252K | Warren Dudley, 46 Sr.
VP of Sales, Marketing ad Bus. Devel. | 279K | Richard Rainey, 34 VP
of Fin. and Admin. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|